Greetings everyone, here is your digest of December Newsletters, along with today's news and updates.
Epclusa most effective for HCV genotype 3 vs. other DAAs
December 5, 2016
Researchers in the Netherlands found that Sovaldi plus velpatasvir, known as Epclusa in the United States, was the most effective regimen for the treatment of hepatitis C genotype 3 infection compared with other direct-acting antiviral regimens, according to published findings.
“The findings of our network meta-analysis can be used to prioritize DAA regimens for HCV genotype 3 patients in guidelines and clinical practice,” Joost P.H. Drenth, MD, PhD, professor of gastroenterology and hepatology, Radboud University Medical Center, the Netherlands, and colleagues wrote.
Frontline Medical News
Publish date: November 29, 2016
By: Richard Pizzi
BASL - British Association for the Study of the Liver
Hepatocellular carcinoma increase rate slows in USA
The overall rate of increase in hepatocellular carcinoma (HCC) slowed between 2010 and 2012, found a nationwide US study. However, it did increase in some sub-groups such as men aged 55 to 64, and whites/Caucasians.
Researchers at Baylor College of Medicine in Texas analysed data from the US Cancer Statistics registry, which covers 97% of the population of all 50 states.
They found that the HCC incidence increased from 4.4/100,000 in 2000 to 6.7/100,000 in 2012, increasing by 4.5% annually between 2000 and 2009, but only by 0.7% annually between 2010 and 2012.
The average annual percentage change (AAPC) between 2000 and 2012 was higher in men (increase of 3.7%) than women (increase of 2.7%), and highest in 55 to 59-year-olds (AAPC 8.9%) and 60 to 64-year-olds (AAPC 6.4%).
By 2012, rates in Hispanics surpassed those in Asians, and rates in Texas surpassed those in Hawaii (9.71/100,000 vs 9.68/100,000). Geographic variation within individual race and ethnic groups was observed, but rates were highest in all major race and ethnic groups in Texas.
Reference - Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. White DL, Thrift AP, Kanwal F et al. Gastroenterology. 2016 Nov 23 [Epub ahead of print]
Read all research and news updates, here...
Dr. Joseph S. Galati
Discussions about the liver and everything else related to health and wellness.
Visit The Blog of Dr. Joseph S. Galati
Fatty Liver: What Treatment is Available?
Published on Dec 4, 2016
Joe Galati, M.D.
Fatty liver can be complicated by cirrhosis and liver cancer, and the need for liver transplant. Fatty liver disease should not be ignored. New research drugs and medicines are being developed.
In The News
CHARLESTON, W.Va. — Karen Bowling, cabinet secretary for the State Department of Health and Human Resources Bureau for Public Health, told members of a legislative interim committee what’s working and what’s not when it comes to fighting West Virginia’s drug epidemic.
Hundreds of VA dental patients possibly exposed to HIV, hepatitis
WHO Prequalifies First Hepatitis C Diagnostic
VA dentist resigns after possibly infecting 600 veterans with HIV and hepatitis
The Five by Alan Franciscus – I have picked five abstracts that I think are some of the most interesting including alcohol and treatment, HBV reactivation during and after HCV treatment, patient descriptions of fatigue (my favorite), curing HCV and diabetes, and the cost of generic direct-acting antiviral medications.
HealthWise by Lucinda K. Porter—AASLD – Lucinda has picked various abstracts such as payer treatment restrictions, pre-existing liver disease treatment and outcomes of breast cancer, hepatitis C reactivation in patients with cancer, alcohol and treatment outcome, fatigue, HAV and HBV vaccination in people with liver disease, and surveillance and screening of liver cancer.
Under the Umbrella by Matthew Zielske –The challenges of proving what we know – Matthew writes about the importance of communication and some of the discrimination that people face when seeking information and medical care.
HCV Advocate Pipeline has been updated with phase 2 information about AbbVie’s combination of glecaprevir plus pibrentasvir to treat genotype 1, 3,4, 5, and 6. Hint – very high cure rates.
Check out our new Easy C fact sheets:
What are RAVs
Taking HCV Meds – Adherence
We have updated our HCSP fact sheet:
Adherence to HCV Therapy
Coming Next Month
The Top News Stories of 2016
A New Fact Sheet Series: Harm Reduction
Many thanks for your continued support,
Alan and the HCV Advocate team
News from the 2016 AASLD Liver Meeting
New pangenotypic combinations
Hepatitis C genotype 3
Real world treatment performance matches the best clinical trial results
Treatment scale-up and the continuum of care
Liver cancer in people treated with direct-acting antivirals
Hepatitis B treatment
Generic hepatitis C drugs
HEP Winter 2016 - Special Issue
Through the Uprights
Alive and Kicking
Beware Herbal and Dietary Supplements
The New York City Hepatitis C Task Force
Share this road map of resources for New York City immigrants with clients.
New HCV Action case studies highlight effective testing services
GI & Hepatology News
Over 17,000 gastroenterologists and hepatologists rely on GI & Hepatology News every month to cover the world of medicine with breaking news, on-site medical meeting coverage, and expert perspectives both in print and online. The official newspaper of the AGA Institute was launched in partnership with IMNG in January 2007.
December 2016 issue of GI & Hepatology
NIH News in Health
Cast Toxins From Your Living Space
A Modern Take on an Ancient Practice
Oxygen Therapy for Patients with COPD
When Clinical Research Is in the News
Featured Website: College Drinking: Changing the Culture
More than 1,000 medications, with acetaminophen being the most common, have been associated with drug-induced liver injury (DILI).
Sift through highlights from The Liver Meeting arranged by the following topics;
1) AASLD Summary - Watch Expert Review
3) Safety Profile
4) Ethnicity on HCV Patient Outcomes
6) Sofosbuvir or Daclatasvir-Based Regimens
7) Key data indexed by pharmaceutical company
8) Treatment with direct-acting antiviral (DAA) agents; Veterans and Elderly
9) HCV and Liver Disease; Fibrosis, Cirrhosis, Liver Cancer, Liver Transplant, Liver Failure, and Fatty Liver/non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
10) Latest News